Company Overview of Abramson Family Cancer Research Institute
Key Executives for Abramson Family Cancer Research Institute
Compensation as of Fiscal Year 2014.
Abramson Family Cancer Research Institute Key Developments
Myriad Genetics, Inc. and Memorial Sloan Kettering Cancer Center, Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and Other Laboratories Team Up in Innovative Collaboration to Accelerate Hereditary Cancer Research
Jun 2 14
Myriad Genetics Inc. and Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in a new partnership that will dramatically advance the understanding of the risks associated with multiple cancer genes that are being analyzed through next generation sequencing technology. Specifically, the partners will collaborate on the creation of a research study called the Prospective Registry of Multiplex Testing (PROMPT). The goals of the study are three-fold: to create an online registry of individuals consenting to a prospective follow up after having been tested with a pan-cancer panel test such as Myriad's myRisk(TM) Hereditary Cancer; to provide infrastructure for the curation of specific genetic variants detected; and to facilitate additional studies to characterize the significance of the genetic mutations. Myriad will contribute thousands of genetic mutations and its scientific expertise gained from having tested over 1.3 million patients for hereditary cancer risk.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries